Shu is first expert from Asia to receive the award. According to ARO, Shu was awarded for his collaborative and continued ...

SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to ...

SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to ...

DB-OTO is designed to restore hearing in individuals with OTOF gene mutations by delivering a functional otoferlin protein, essential for communication between sensory cells of the inner ear and the ...

DB-OTO treats abnormalities in the OTOF gene. OTOF produces otoferlin, a protein that transmits auditory signals to the brain. If otoferlin is not adequately expressed, "auditory neuropathy ...

It is caused by variants in the OTOF gene, which lead to a lack of a functional otoferlin protein critical for communication between the inner ear’s sensory cells and the auditory nerve.

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) says that its investigational gene therapy DB-OTO showed clinically-meaningful hearing improvements in nearly all children with profound genetic ...

All aim to fix an ultra-rare form of deafness caused by mutations in a gene known as OTOF. Deep within the ear, thousands of specialized cells transmute the vibrations of sound into a signal passed to ...

However, otoferlin-related hearing loss is ultra-rare. This specific condition is caused by variants in the OTOF gene, which leads to a lack of a functional otoferlin protein that is critical for the ...

Association for Research in Otolaryngology’nin 48. Annual MidWinter Meeting’inde sunulan veriler, otoferlin (OTOF) gen varyantları olan çocuklarda işitme ve konuşma gelişiminde önemli iyileşmeler ...